Intratumoral Immunotherapy With the TLR7/8 Agonist 3m-052

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-1-s1-p138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

The TLR7/8 Agonist R848 Remodels Tumor and Host Responses to Promote Survival in Pancreatic Cancer

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

Addressing the Adult Soft Tissue Sarcoma Microenvironment With Intratumoral Immunotherapy

Sarcoma
Nuclear MedicineRadiologyImagingOncology
2018English

The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia

Cancer Research
Cancer ResearchOncology
2018English

Protective T Cell Immunity in Mice Following Protein-Tlr7/8 Agonist-Conjugate Immunization Requires Aggregation, Type I IFN, and Multiple DC Subsets

Journal of Clinical Investigation
Medicine
2011English

TLR9 Agonist, but Not TLR7/8, Functions as an Adjuvant to Diminish FI-RSV Vaccine-Enhanced Disease, While Either Agonist Used as Therapy During Primary RSV Infection Increases Disease Severity

Vaccine
Molecular MedicinePublic HealthVeterinaryMicrobiology EnvironmentalImmunologyInfectious DiseasesOccupational Health
2009English

Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity

English

The TLR7 Agonist Imiquimod as an Adjuvant for Radiotherapy-Elicited in Situ Vaccination Against Breast Cancer

OncoImmunology
OncologyAllergyImmunology
2013English

RNA‐Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators

Small
Materials ScienceNanoscienceEngineeringBiomaterialsMedicineBiotechnologyNanotechnologyChemistry
2019English

TLR7/8 Adjuvant Overcomes Newborn Hyporesponsiveness to Pneumococcal Conjugate Vaccine at Birth

JCI insight
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy